Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Separately, ValuEngine lowered shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th.

Shares of Bellerophon Therapeutics (NASDAQ BLPH) traded down 3.51% during trading on Thursday, reaching $1.10. The company had a trading volume of 197,179 shares. The stock has a 50 day moving average of $1.29 and a 200 day moving average of $1.34. Bellerophon Therapeutics has a 52-week low of $0.43 and a 52-week high of $1.98. The stock’s market capitalization is $39.06 million.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. Equities research analysts forecast that Bellerophon Therapeutics will post ($1.12) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Bellerophon Therapeutics, Inc. (BLPH) Lowered to Hold at Zacks Investment Research” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/bellerophon-therapeutics-inc-blph-lowered-to-hold-at-zacks-investment-research/1534799.html.

A number of hedge funds have recently modified their holdings of BLPH. Susquehanna International Group LLP acquired a new stake in shares of Bellerophon Therapeutics during the second quarter worth $1,316,000. Vanguard Group Inc. boosted its stake in shares of Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after buying an additional 211,111 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Bellerophon Therapeutics during the first quarter worth $125,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after buying an additional 238,300 shares during the last quarter. Hedge funds and other institutional investors own 45.85% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.